Angioplasty, or the removal of plaque in arteries, is a short-term solution for a chronic problem in patients with cardiovascular disease. Following the procedure, a bare metal stent (metal tube) is placed to physically keep the vessel from narrowing. Recently, new drug-eluting stents containing either paclitaxel or rapamycin have been approved for treatment of restenosos in the coronary arteries. The drug helps to prevent hardening of the artery in conjunction with the placement of the bare metal stent. Cardio-Pac and Cardio-Doc, microtubule stabilizer taxol based products, are being developed by Chikujee to be used in conjunction with stents to prevent various forms of arterial restenosis. Chikujees’ current research on these taxol based products is focused on coronary and peripheral artery restenosis.

Coronary Artery Restenosis
Approximately 800,000 procedures of coronary artery stenting are performed in the United States alone every year. Although the results of drug-eluting stents are encouraging, there may be complications after surgery, such as weakening of the artery wall, blood clot formation, and an increased risk of myocardial infarction when the vessel doesn’t heal completely. Cardio-Pac and Cardio-Doc are currently in pre-clinical development for coronary artery restenosis.

Product Portfolio

Cardio-Pac: Paclitaxel based multifunctional NanoBindi

Cardio-Doc: Docetaxel based multifunctional NanoBindi